NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Showcase DERMAdoctor’s Eczema Balm on Return QVC® Appearance
September 12 2022 - 6:50AM
Business Wire
Calm Cool + Corrected Eczema + Dermatitis
Clinical Repair Balm to be Featured on “Girls’ Night In with
Courtney & Jane” on September 13 at 9 p.m. Eastern Time
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality, scientifically
formulated eyecare and skincare products, announces that Chief
Product Officer Audrey Kunin, MD will return to the QVC network for
her third on-air appearance this year to discuss DERMAdoctor’s
revolutionary Calm Cool + Corrected 1% Colloidal Oatmeal Eczema +
Dermatitis Clinical Repair Balm. This problem-solving eczema
treatment will be featured on “Girls’ Night In with Courtney &
Jane” on Tuesday, September 13 at 9 p.m. Eastern time.
“It’s particularly timely to highlight Calm Cool + Corrected 1%
Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm’s
significant benefits just weeks before the October 1st start of
National Eczema Awareness Month,” said Dr. Kunin. “Eczema often
flares with seasonal changes and our Calm Cool + Corrected Eczema
balm provides temporary relief of minor irritations and itching,
while maximizing hydration to calm and soothe affected skin.
Importantly, our balm is gentle enough to be used anywhere eczema
appears on the body. It is one of the many DERMAdoctor products we
created to provide real solutions for real people with real skin
concerns.”
Eczema affects an estimated 31 million Americans. Although it is
typically thought to be a childhood condition, more than 16 million
U.S. adults are afflicted by eczema, according to the Asthma and
Allergy Foundation of America. Atopic dermatitis, the most common
form of eczema, is a chronic, inflammatory skin disease that
results in widespread rashes and patches of itchy skin. Those
afflicted report lifestyle limitations that affect their daily
activities and cause them to avoid social interactions.
Dr. Kunin is a board-certified dermatologist, author, clinician,
educator, television personality and recognized trailblazer in the
skincare industry. She founded DERMAdoctor to deliver on the
promise that clinical skin therapy can be simple and easy.
DERMAdoctor products are scientifically formulated to provide
measurable results for common skincare concerns that have been
overlooked by the beauty industry.
Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis
Clinical Repair Balm incorporates a special form of eczema-active
1% colloidal oatmeal with enhanced beta glucan, an advanced complex
of ceramides and essential lipids, and dermatologic botanicals.
Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis
Clinical Repair Balm has received the National Eczema Association
(NEA) Seal of Acceptance™, which is granted in recognition of
products that meet the NEA’s rigorous standards for providing
benefits and improving the quality of life for people with eczema
and sensitive skin.
About NovaBay Pharmaceuticals, Inc:
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that
develops and sells scientifically created and clinically proven
consumer products for the eyecare and skincare markets. Avenova® is
the most prescribed antimicrobial lid and lash spray and
DERMAdoctor® is a premium skincare brand offering more than 30
dermatologist-developed skincare products sold through traditional
domestic retailers, digital beauty channels and international
distributors.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current product offerings, marketing efforts, and any
future revenue that may result from selling such products, as well
as generally the Company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, the integration of DERMAdoctor’s business
into the Company’s business, the possibility that the available
market for the Company’s products will not be as large as expected,
the Company’s products will not be able to penetrate one or more
targeted markets, and revenues will not be sufficient to meet the
Company’s cash needs. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220912005244/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024